Novoheart Holdings Inc. — Investor Relations & Filings

Novoheart Holdings Inc. is a stem cell biotechnology holding company specializing in the engineering of bioartificial human heart surrogates and next-generation cardiac tissue prototypes. The company utilizes state-of-the-art bioengineering approaches and human stem cell-derived cardiomyocytes to create its core product, the mini-Heart Platform. This platform consists of advanced engineered-tissue formats designed for comprehensive assessment of cardiac functional outputs. Novoheart provides bioengineered human cardiac tissue models and related services for drug discovery, disease modeling, and pharmaceutical screening. The platform supports over 12 disease models, including those for Heart Failure with preserved Ejection Fraction (HFpEF), Arrhythmias, and COVID-19 cardiotoxicity. By offering human-relevant models, Novoheart aims to accelerate research, improve efficacy, and reduce costs by eliminating reliance on animal testing.